<DOC>
	<DOCNO>NCT00924053</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability pharmacokinetics ( much drug get blood long take body get rid ) single dose EGT0001474 give patient Type 2 diabetes . The study also evaluate EGT0001474 affect amount glucose produce body urine .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Study EGT0001474 Subjects With Type 2 Diabetes</brief_title>
	<detailed_description>EGT0001474 compound may inhibit effect compound body know sugar transporter . The use EGT0001474 may enhance elimination glucose blood increase amount urine produce . This would help prevent abnormal decrease blood sugar ( hypoglycemia ) fasting meal without increase insulin secretion ( may result weight gain abnormal increase blood sugar know Type 2 diabetes ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female age 18 70 diagnose Type 2 diabetes . Body mass Index ( BMI ) 18 kg/m2 37 kg/m2 . HbA1c level 6.5 9.0 ( inclusive ) upper limit normal HbA1c assay 6.4 % 6.29.0 % ( inclusive ) upper limit normal HbA1c assay 6.1 % fast plasma glucose 110 240 mg/dL ( inclusive ) diabetic medication . If take drug diabetes , must medically able willing discontinue diabetes medication duration study . Female subject must surgically sterilize postmenopausal . Nonsmoker least 3 month . Negative alcohol screen . Type 1 diabetes . Use insulin therapy oral antidiabetic medication metformin , sitagliptin sulfonylurea . Sitting blood pressure 150/95 mmHg 2 evaluation least 10 minute apart screen . Treatment investigational drug within 30 day 7 halflives , whichever longer . Previous treatment EGT0001474 . Vaccination within 30 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Diabetes Mellitus Type 2</keyword>
</DOC>